WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
April 26, 2004
--------------
Date of Report (Date of earliest event reported)
OSI PHARMACEUTICALS, INC.
-------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-15190 13-3159796
--------- ------- ----------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation) File Number) Identification No.)
58 SOUTH SERVICE ROAD
MELVILLE, NY 11747
---------------------------
(Address of principal executive offices)
(631) 962-2000
-----------------------
(Registrant's telephone number, including area code)
N/A
---------------
(Former name or former address,
if changed since last report.)
ITEM 5. OTHER EVENTS
On April 26, 2004, OSI Pharmaceuticals, Inc., a Delaware corporation
(the "Company") announced certain results from a non-small cell lung cancer
Phase III study of Tarceva(TM). Details regarding the results are contained in
the Company's press release, dated April 26, 2004, attached as Exhibit 99, and
incorporated herein by reference.
ITEM 7. EXHIBITS
EXHIBIT NO. DESCRIPTION
99 Press release, dated April 26, 2004.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: April 26, 2004 OSI PHARMACEUTICALS, INC.
By: /s/ Robert L. Van Nostrand
-------------------------------------
Robert L. Van Nostrand
Vice President and Chief Financial
Officer (Principal Financial Officer)
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
99 Press release, dated April 26, 2004.